We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Sensitive Tool Implicates New Rhinovirus in Pediatric Respiratory Infections

By Biotechdaily staff writers
Posted on 28 Nov 2007
A rapid, sensitive, and inexpensive diagnostic tool implicated a new human rhinovirus (HRV) as the cause of severe pediatric respiratory tract infections in Europe.

Scientists used the new tool, which is called MassTag polymerase chain reaction (PCR), to investigate 97 samples, collected over a three-year period, from children with hospital-admitted, acute respiratory illness where no pathogen had been identified by routine laboratory testing. More...
HRVs were the most frequent viruses detected in the sample set, representing 75% of the identified viruses.

Human rhinoviruses are frequent causes of respiratory illness worldwide. Although they are most commonly associated with self-limited upper respiratory tract disease, lower respiratory tract infections related to HRVs are being increasingly reported in infants, elderly persons, and immunocompromised patients. HRVs are also implicated in exacerbations of asthma, chronic bronchitis, and acute bronchiolitis.

To detect pathogens, MassTag PCR uses small molecular tags to detect up to 30 different pathogens simultaneously in one test. Genetic material from a throat swab or other sample is extracted and then mixed with PCR primers--short pieces of DNA that recognize specific nucleic acid sequences within the genomes of the target viruses or bacteria. If a throat swab contains pathogens with nucleic acid sequences that match those of the primers, then the primers will copy the target DNA several million times. Likewise, the molecular tags, different in mass for each of the primers, are also amplified, making them easily detectable by mass spectrometry, a technology that identifies molecules based on their masses.

"The results of the study confirm our earlier findings in New York, namely, that these viruses represent a clinically significant but previously unappreciated species within the entero-/rhinoviruses, one of the longest known and most intensely studied virus groups,” stated Thomas Briese, Ph.D., associate professor of clinical epidemiology at Columbia University Mailman School of Public Health's Center for Infection and Immunity (New York, NY, USA) who coordinated the study. "We urgently need drugs and vaccines to address the challenges they pose to child health.”

The study appeared in the November 2007 online edition of the Journal of Infectious Diseases.


Related Links:
Columbia University Mailman School of Public Health

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.